Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

V1RG9 Inhibitors

V1RG9 inhibitors are a chemical class that targets a specific biological pathway involving the V1RG9 receptor, a molecular structure which plays a crucial role in various biochemical processes. The inhibitors designed to affect this receptor work by binding to it and altering its natural function. Typically, these inhibitors are small molecules that can specifically interact with the V1RG9 receptor due to their unique chemical composition and structure. The design of these inhibitors is often a result of extensive research into the molecular shape and electronic characteristics of the target receptor, enabling a precise fit between the inhibitor and the receptor, much like a key fits into a lock. This specificity is a result of the careful choice of functional groups within the inhibitor molecules that can engage with corresponding sites on the receptor.

The mode of action of V1RG9 inhibitors involves preventing the normal interaction of the receptor with its endogenous ligands, which are the molecules that naturally bind to and activate or deactivate the receptor. By binding to the receptor, these inhibitors can either block the binding site or induce a conformational change in the receptor that results in decreased activity or complete inactivation. The structural diversity of V1RG9 inhibitors is vast, with various classes of compounds being identified that can perform this function. The complexity of the interactions between these inhibitors and the V1RG9 receptor is a subject of ongoing research, focusing on understanding the subtleties of the receptor's role in molecular signaling pathways. This detailed knowledge of molecular interactions is crucial for the development of V1RG9 inhibitors, which are synthesized through complex organic chemistry processes and optimized through iterative cycles of design, synthesis, and testing.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin selectively inhibits mTOR (mechanistic target of rapamycin), which is a downstream effector in the PI3K/AKT pathway. V1RG9 is known to function downstream of this pathway, so its function is inhibited by rapamycin.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is a potent inhibitor of the PI3K, which leads to the suppression of the PI3K/AKT pathway. The inhibition of this pathway decreases the activity of V1RG9, as it operates downstream of PI3K signaling.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is a PI3K inhibitor that robustly blocks the phosphorylation and activation of AKT, thereby reducing the activation of downstream targets, including V1RG9.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 is a selective inhibitor of MEK, which prevents the activation of MAPK/ERK pathway. Given that V1RG9 is regulated by the MAPK/ERK signaling, its activity is indirectly diminished by PD98059.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 is another MEK inhibitor that acts upstream of ERK, resulting in the inhibition of the MAPK/ERK signaling pathway, thus indirectly reducing the functional activity of V1RG9.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 is a selective inhibitor of p38 MAPK. The inhibition of p38 MAPK can impact the function of V1RG9 if V1RG9’s activity is modulated by the p38 MAPK pathway.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. Inhibition of JNK can lead to decreased activity of V1RG9 if it is influenced by the JNK signaling cascade.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$102.00
$138.00
14
(1)

Triciribine specifically inhibits the phosphorylation and activation of AKT, leading to a downstream reduction in V1RG9 activity if V1RG9 is regulated by the AKT pathway.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib is a proteasome inhibitor that can decrease the degradation of IκB, leading to inhibition of NF-κB translocation to the nucleus. If V1RG9 is NF-κB responsive, this would reduce its activity.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Sunitinib is a tyrosine kinase inhibitor that may block receptor tyrosine kinases that are involved in the regulation of V1RG9.